Olfactory outcomes in Zika virus-associated Guillain-Barré syndrome.
Guillain-Barré syndrome
Zika
hyposmia
olfaction
olfactory threshold
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
02
06
2022
received:
24
03
2022
accepted:
09
06
2022
pubmed:
15
6
2022
medline:
9
8
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
Zika virus (ZIKV) infection has been associated with Guillain-Barré syndrome (GBS). However, little is known about the consequence of ZIKV infection on olfaction in humans. Immediately before the COVID-19 outbreak, we prospectively investigated the olfactory capacities of 19 patients with ZIKV-associated GBS from the French West Indies and compared them to nine controls from the same population, with GBS of similar severity but independent of ZIKV infection. To provide further evidence that ZIKV infection induces smell alteration, we investigated the consequences of ZIKV infection on olfactory abilities using a mouse model. Patients with GBS-ZIKA+ had poorer olfactory function than GBS-non-ZIKA, even 1-2 years after the acute phase. The proportion of patients with hyposmia was significantly higher in the GBS-ZIKA+ than in the GBS-non-ZIKA group (68.4% vs. 22.2%, p = 0.042). These deficits were characterized by lower threshold and identification scores and were independent from GBS severity. Additionally, ZIKV infection was found to impair olfaction in immunodeficient mice infected with ZIKV. High viral load was observed in their olfactory system and downstream brain structures. ZIKV promoted both cellular damage in the olfactory neuroepithelium and protracted inflammation of the olfactory bulb, likely accounting for smell alteration. Patients with ZIKV-related GBS had poorer long-term olfactory function than patients with GBS-non-ZIKA, and ZIKV-infected mice are hyposmic. These observations suggest that ZIKV belongs on the list of viruses affecting the olfactory system. Clinical evaluation of the olfactory system should be considered for ZIKV-infected patients.
Sections du résumé
BACKGROUND AND PURPOSE
Zika virus (ZIKV) infection has been associated with Guillain-Barré syndrome (GBS). However, little is known about the consequence of ZIKV infection on olfaction in humans.
METHODS
Immediately before the COVID-19 outbreak, we prospectively investigated the olfactory capacities of 19 patients with ZIKV-associated GBS from the French West Indies and compared them to nine controls from the same population, with GBS of similar severity but independent of ZIKV infection. To provide further evidence that ZIKV infection induces smell alteration, we investigated the consequences of ZIKV infection on olfactory abilities using a mouse model.
RESULTS
Patients with GBS-ZIKA+ had poorer olfactory function than GBS-non-ZIKA, even 1-2 years after the acute phase. The proportion of patients with hyposmia was significantly higher in the GBS-ZIKA+ than in the GBS-non-ZIKA group (68.4% vs. 22.2%, p = 0.042). These deficits were characterized by lower threshold and identification scores and were independent from GBS severity. Additionally, ZIKV infection was found to impair olfaction in immunodeficient mice infected with ZIKV. High viral load was observed in their olfactory system and downstream brain structures. ZIKV promoted both cellular damage in the olfactory neuroepithelium and protracted inflammation of the olfactory bulb, likely accounting for smell alteration.
CONCLUSIONS
Patients with ZIKV-related GBS had poorer long-term olfactory function than patients with GBS-non-ZIKA, and ZIKV-infected mice are hyposmic. These observations suggest that ZIKV belongs on the list of viruses affecting the olfactory system. Clinical evaluation of the olfactory system should be considered for ZIKV-infected patients.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2823-2831Investigateurs
Sylvie Abel
(S)
Ornella Cabras
(O)
Athéna Marquise
(A)
Mathilde Pircher
(M)
Aïssatou Signate
(A)
Christelle Celeste
(C)
Angela Lackmy
(A)
Guillaume Lepage
(G)
Quentin Lobjois
(Q)
Aimée Petit
(A)
Benoît Tressières
(B)
Natacha Teissier
(N)
Tan-Phuc Buivan
(TP)
Laurine Conquet
(L)
Hélène Laude
(H)
Estelle Mottez
(E)
Fabien Taieb
(F)
Marie-Noëlle Ungeheuer
(MN)
Informations de copyright
© 2022 European Academy of Neurology.
Références
Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539.
Lannuzel A, Fergé JL, Lobjois Q, et al. Long-term outcome in neuroZika: when biological diagnosis matters. Neurology. 2019;92(21):e2406-e2420.
Leonhard SE, Halstead S, Lant SB, et al. Guillain-Barré syndrome during the zika virus outbreak in Northeast Brazil: an observational cohort study. J Neurol Sci. 2021;420:117272.
Koike H, Chiba A, Katsuno M. Emerging infection, vaccination, and Guillain-Barré syndrome: a review. Neurol Ther. 2021;10(2):523-537.
Garcez PP, Loiola EC, Madeiro da Costa R, et al. Zika virus impairs growth in human neurospheres and brain organoids. Science. 2016;352(6287):816-818.
Lazear HM, Govero J, Smith AM, et al. A mouse model of zika virus pathogenesis. Cell Host Microbe. 2016;19(5):720-730.
Figueiredo CP, Barros-Aragão FGQ, Neris RLS, et al. Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. Nat Commun. 2019;10:3890.
Ozdener MH, Donadoni M, Cicalese S, et al. Zika virus infection in chemosensory cells. J Neurovirol. 2020;26(3):371-381.
Pan American Health Organization / World Health Organization. PAHO WHO | Zika Resources: Case Definitions; 2016. http://www.paho.org/hq/index.php?option=com_content&view=article&id=11117%3Azika-resources-case-definitions&catid=8424%3Acontents&Itemid=41532&lang=en. Accessed April 1, 2016.
Rozé B, Najioullah F, Fergé JL, et al. Guillain-Barré syndrome associated with zika virus infection in Martinique in 2016: a prospective study. Clin Infect Dis. 2017;65(9):1462-1468.
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Ann Neurol. 1998;44(5):780-788.
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33-43.
Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve. 1991;14(11):1103-1109.
Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22(1):39-52.
Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin' sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol. 2019;276(3):719-728.
Colle R, El Asmar K, Verstuyft C, et al. The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment. Psychol Med. 2020;22:1-9.
Yahiaoui-Doktor M, Luck T, Riedel-Heller SG, Loeffler M, Wirkner K, Engel C. Olfactory function is associated with cognitive performance: results from the population-based LIFE-adult-study. Alzheimers Res Ther. 2019;11(1):43.
Wechsler D. Wechler Memory Scale-Revised. Psychological Corp; 1987.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
Manet C, Simon-Lorière E, Jouvion G, et al. Genetic diversity of collaborative cross mice controls viral replication, clinical severity, and brain pathology induced by zika virus infection, independently of Oas1b. J Virol. 2020;94(3):e01034-e01019.
Deng YQ, Zhang NN, Li XF, et al. Intranasal infection and contact transmission of zika virus in Guinea pigs. Nat Commun. 2017;8:1648.
Lazarini F, Katsimpardi L, Levivien S, et al. Congenital cytomegalovirus infection alters olfaction before hearing deterioration in mice. J Neurosci. 2018;38(49):10424-10437.
de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021;13(596):eabf8396.
de Chaumont F, Dallongeville S, Chenouard N, et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat Methods. 2012;9(7):690-696.
Chen M, Reed RR, Lane AP. Chronic inflammation directs an olfactory stem cell functional switch from Neuroregeneration to immune defense. Cell Stem Cell 2019;25(4):501-513. e5.
Lazarini F, Levivien S, Madec Y, et al. Olfactory function in congenital cytomegalovirus infection: a prospective study. Eur J Pediatr. 2022;181:1859-1869. doi:10.1007/s00431-022-04375-1
Addison AB, Wong B, Ahmed T, et al. Clinical olfactory working group consensus statement on the treatment of postinfectious olfactory dysfunction. J Allergy Clin Immunol. 2021;147(5):1704-1719.
Hopkins C, Alanin M, Philpott C, et al. Management of new onset loss of sense of smell during the COVID-19 pandemic-BRS consensus guidelines. Clin Otolaryngol. 2021;46(1):16-22.